VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

Nature Medicine

Volumn 23, Issue 5, 2017, Pages 551-555

  Gao, Jianjun ^a   Ward, John F ^a   Pettaway, Curtis A ^a   Shi, Lewis Z ^a   Subudhi, Sumit K ^a   Vence, Luis M ^a   Zhao, Hao ^a   Chen, Jianfeng ^a   Chen, Hong ^a   Efstathiou, Eleni ^a   Troncoso, Patricia ^a   Allison, James P ^a   Logothetis, Christopher J ^a   Wistuba, Ignacio I ^a   Sepulveda, Manuel A ^b   Sun, Jingjing ^a   Wargo, Jennifer ^a   Blando, Jorge ^a   Sharma, Padmanee ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; PROGRAMMED DEATH 1 LIGAND 1; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VISTA PROTEIN; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD274 PROTEIN, HUMAN; CD274 PROTEIN, MOUSE; DIES1 PROTEIN, MOUSE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; VISTA PROTEIN, HUMAN;

ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; MACROPHAGE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; ADULT; AGED; ANIMAL; DISEASE MODEL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IN VITRO STUDY; MALE; METABOLISM; MIDDLE AGED; MOUSE; NEOADJUVANT THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS; T LYMPHOCYTE; TISSUE MICROARRAY; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; B7 ANTIGENS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IN VITRO TECHNIQUES; MACROPHAGES; MALE; MEMBRANE PROTEINS; MICE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TISSUE ARRAY ANALYSIS;

EID: 85016090030     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4308     Document Type: Article

References (20)

1. Sharma, P. & Allison, J. P. Cell 161, 205-214 (2015).
2. Sharma, P. & Allison, J. P. Science 348, 56-61 (2015).
3. Kwon, E. D. et al. Lancet Oncol. 15, 700-712 (2014).
4. Topalian, S. L. et al. N. Engl. J. Med. 366, 2443-2454 (2012).
5. Subudhi, S. K. et al. Proc. Natl. Acad. Sci. USA 113, 11919-11924 (2016).
6. Liakou, C. I. et al. Proc. Natl. Acad. Sci. USA 105, 14987-14992 (2008).
7. Ng Tang, D. et al. Cancer Immunol. Res. 1, 229-234 (2013).
8. Carthon, B. C. et al. Clin. Cancer Res. 16, 2861-2871 (2010).
9. Freeman, G. J. et al. J. Exp. Med. 192, 1027-1034 (2000).
10. Lines, J. L., Sempere, L. F., Broughton, T., Wang, L. & Noelle, R. Cancer Immunol. Res. 2, 510-517 (2014).
11. Chen, H. et al. Proc. Natl. Acad. Sci. USA 106, 2729-2734 (2009).
12. Biswas, S. K. & Mantovani, A. Nat. Immunol. 11, 889-896 (2010).
13. Gao, J. et al. Oncogene 34, 5411-5417 (2015).
14. Wimberly, H. et al. Cancer Immunol. Res. 3, 326-332 (2015).
15. Stack, E. C., Wang, C., Roman, K. A. & Hoyt, C. C. Methods 70, 46-58 (2014).
16. Amir, el-A. D. et al. Nat. Biotechnol. 31, 545-552 (2013).
17. Levine, J. H. et al. Cell 162, 184-197 (2015).
18. Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C. & Greenberg, N. M. Cancer Res. 57, 3325-3330 (1997).
19. Shi, L. Z. et al. Nat. Commun. 7, 12335 (2016).
20. Chen, P. L. et al. Cancer Discov. 6, 827-837 (2016).